{"id":189201,"date":"2023-10-03T07:47:22","date_gmt":"2023-10-03T11:47:22","guid":{"rendered":"http:\/\/stateofthenation.co\/?p=189201"},"modified":"2023-10-03T07:47:52","modified_gmt":"2023-10-03T11:47:52","slug":"pure-evil-safety-trials-start-for-babies-6-months-5-yrs-pfizer-mrna-nanoparticle-bioweapon-injected-along-with-other-childhood-vaccines","status":"publish","type":"post","link":"https:\/\/stateofthenation.co\/?p=189201","title":{"rendered":"

PURE EVIL: ‘Safety’ Trials Start for Babies 6 Months-5 Yrs, Pfizer mRNA Nanoparticle Bioweapon Injected Along With Other Childhood Vaccines<\/b><\/h2>"},"content":{"rendered":"

Duke Leads CDC Study Target 6 Month to Under 5-Year-Old Children–Pfizer mRNA + Simultaneous Childhood Vaccines\u2014 Safety Response<\/h3>\n

Lioness of Judah Ministry<\/p>\n

Shoutout to Dr. Roger Hodkinson<\/a> for sharing this important information.<\/p>\n

Children aged 6 months to 5 years old are being recruited into a Duke University-led study to determine the safety of simultaneous mRNA COVID-19 vaccine with other childhood vaccines.<\/p>\n

A study seeks to assess any adverse reactions when this young cohort are vaccinated both with mRNA COVID-19<\/strong> vaccines<\/strong> and other standard childhood vaccines such as the Pneumococcal, DTaP, Haemophilus Influenzae Type B, MMR, Varicella, MMRV, Hepatitis A, Inactivated Poliovirus, Hepatitis B, Rotavirus, Influenza vaccines<\/strong>.<\/p>\n

trialsitenews.com<\/a> reports:<\/p>\n

Young children aged 6 months to 5 years old are being recruited into a Duke University led study to determine the safety of simultaneous mRNA COVID-19 vaccine with other childhood vaccines. TrialSite has gone on the record now for nearly a year raising the issue of safety involving simultaneous vaccination of MRNA COVID-19 vaccines with other childhood vaccines. Now, a study which commenced in September led by Duke in collaboration with several other medical centers seeks to assess any adverse reactions when this young cohort are vaccinated both with mRNA COVID-19 vaccines and other standard childhood vaccines such as the Pneumococcal, DTaP, Haemophilus Influenzae Type B, MMR, Varicella, MMRV, Hepatitis A, Inactivated Poliovirus, Hepatitis B, Rotavirus, Influenza vaccines.<\/em><\/p>\n

Led by Principal Investigator Michael J. Smith, Duke University, other collaborating institutions include the large integrated health delivery system Kaiser Permanente, Columbia University, Children\u2019s Hospital Medical Center in Cincinnati and the Centers for Disease Control and Prevention (CDC).<\/p>\n

Michael J. Smith, M.D., Principal Investigator<\/strong><\/p>\n

\n
\n
\n\"\"<\/picture>\n
<\/div>\n<\/div>\n<\/figure>\n<\/div>\n

The Core Study<\/strong><\/h2>\n

Starting last month, the study runs for just over a year, concluding December 2024. Involving 600 participants between the ages of 6 months and 5 years of age, a highly vulnerable cohort, this prospective, randomized, parallel assignment clinical trial involves the parent or legal authorized representative (LAR) of the children asses fever and other solicited systemic adverse events on the day of vaccination, known as Day 1, and the next 6 days\u2014meaning through Day 7 after what\u2019s called Visit 1 and Visit 2 using either a web-based data collection system or a paper memory aid.<\/p>\n

The goal here of course is to capture any serious adverse events during this study period. The study was designed to include the assessment of parental\/LAR perceptions about their child\u2019s vaccine schedule by Day 7, after Visit 2.<\/p>\n

The study includes two arms<\/strong>, including the following:<\/p>\n

\n
\n
\n\"\"<\/picture>\n
<\/div>\n<\/div>\n<\/figure>\n<\/div>\n
\n
\n\"\"<\/picture>\n
<\/div>\n<\/div>\n<\/figure>\n

What is the study endpoint?<\/strong><\/h2>\n

The first endpoint or primary outcome involves the number of children in the study with fever (temperature \u2265 38.0\u00b0C or \u2265 100.4\u00b0F) on day 1 and\/or day 2 following Visit 1 and or Visit 2.<\/p>\n

What about secondary endpoints?<\/strong><\/h2>\n

The study team has designed 13 secondary endpoints that TrialSite<\/em> includes below.<\/p>\n

#<\/strong><\/p>\n

Secondary Endpoints<\/strong><\/p>\n

1.<\/p>\n

Number of children with fever (temperature \u2265 38.0\u00b0C or \u2265 100.4\u00b0F) on day 1 and\/or day 2 following Visit 1<\/p>\n

2.<\/p>\n

Number of children with fever (temperature \u2265 38.0\u00b0C or \u2265 100.4\u00b0F) on day 1 and\/or day 2 following Visit 2<\/p>\n

3.<\/p>\n

Number of children with moderate\/severe fever (Grade 2 and\/or 3) on day 1 and\/or day 2 following Visit 1. (Moderate\/severe fever: \u2265 38.4\u00b0C or \u2265 101.2\u00b0F)<\/p>\n

4.<\/p>\n

Number of children with moderate\/severe fever (Grade 2 and\/or 3) on day 1 and\/or day 2 following Visit 2. (Moderate\/severe fever: \u2265 38.4\u00b0C or \u2265 101.2\u00b0F)<\/p>\n

5.<\/p>\n

Number of children with moderate\/severe fever (Grade 2 and\/or 3) on day 1 and\/or day 2 following Visit 1 and Visit 2 combined. (Moderate\/severe fever: \u2265 38.4\u00b0C or \u2265 101.2\u00b0F)<\/p>\n

6.<\/p>\n

Number of children with medical care utilization (medical advice (telephone, patient portal),urgent care visit, emergency department visit, and hospital admission) for fever on day 1 and\/or day 2 following Visit 1.<\/p>\n

7.<\/p>\n

Number of children with medical care utilization (medical advice (telephone, patient portal),urgent care visit, emergency department visit, and hospital admission) for fever on day 1 and\/or day 2 following Visit 2.<\/p>\n

8.<\/p>\n

Number of children with medical care utilization (medical advice (telephone, patient portal), urgent care visit, emergency department visit, and hospital admission) for fever on day 1 and \/or day 2 following Visit 1 and Visit 2 combined.<\/p>\n

9.<\/p>\n

Number of children who received antipyretics on day 1 and\/or day 2 following Visit 1.<\/p>\n

10.<\/p>\n

Number of children who received antipyretics on day 1 and\/or day 2 following Visit 2.<\/p>\n

11.<\/p>\n

Number of children who received antipyretics on day 1 and\/or day 2 following Visit 1 and Visit 2 combined.<\/p>\n

12.<\/p>\n

Tables summarizing each solicited local and systemic reactogenicity event by maximum classification (none, mild, moderate, and severe), as well as by moderate or severe.<\/p>\n

13.<\/p>\n

The number and percent of serious adverse events observed and description of each event.<\/p>\n

Limitations<\/strong><\/h2>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n

Among other challenges including the ethics at this stage of using 6 month and up young children in non-emergency times plus safety signals heretofore not acknowledged (e.g., biodistribution of mRNA) the study monitoring stops at Day 7. What about effects that surface at some later point?<\/p>\n

According to well-known cardiologist-scientist Dr. Peter McCullough who emphasized that this group is not vulnerable to disease but is susceptible to vaccine side effects.\u00a0 McCullough notes about the study\u00a0“Involving 600 participants between the ages of 6 months and 5 years of age, a cohort at low-risk for infectious disease complications but at risk for vaccine injuries including febrile seizures, myocarditis, and vaccine-induced multisystem inflammatory disorder.”<\/p>\n

Duke Clinical Research Institute<\/strong><\/p>\n

\n
\n
\n\"\"<\/picture>\n
<\/div>\n<\/div>\n<\/figure>\n<\/div>\n

Who is Eligible?<\/strong><\/h2>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n

Participants must be in the age range of 6 months and under 5 years of age and must be due to receive the Pfizer-BioNTech mRNA COVID-19 vaccine and at least one other routinely recommended non-live vaccine per CDC or ACIP recommendations.<\/p>\n

Of course, the parent or LAR must have the intention for the child to receive both mRNA COVID-19 vaccine and at least one recommended non-live vaccine, and they (Parent or LAR) must be capable of navigating the written informed consent process.<\/p>\n

Other minimum requirements include the ability for the parent\/LAR to be available for follow-up with minimum telephone access. Also, they must sign a medical release for the child so that study personnel can obtain the child\u2019s medical information as needed.\u00a0\u00a0 Also, the parent\/LAR must be willing to delay the COVID-19 vaccination for their child for up to 3 weeks and they must be able to read either English or Spanish.<\/p>\n

Exclusionary criteria are provided in the underlying clinical trials registry at Clinicaltrials.gov. The list, an extensive one, includes any history of myocarditis\/pericarditis and several other conditions that should be read carefully.<\/p>\n

What are the Trial Site Locations?<\/strong><\/h2>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n

The table below lists trial site locations for this study.<\/p>\n

\n
\n
\n\"\"<\/picture>\n
<\/div>\n<\/div>\n<\/figure>\n<\/div>\n

Lead Research\/Investigator<\/strong><\/h2>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n

Michael J. Smith<\/a>, M.D., Principal Investigator<\/p>\n

References<\/p>\n

Clinicaltrials.gov<\/a><\/p>\n

\n
\n<\/div>\n

Phasing out the human race will solve every problem on earth, social and environmental<\/em> – David Foreman<\/h4>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n

Mengeles From the FDA Mass Murder Advisory Committee Discuss Clinical Trials for Babies: A 17-Month-Old Baby Received a Second Dose Despite Multiple Seizures From the First<\/h2>\n
\n
Lioness of Judah Ministry<\/a><\/div>\n
\u00b7<\/div>\n
June 15, 2022<\/div>\n<\/div>\n
\"Mengeles<\/picture><\/a><\/div>\n
\n

Exposing The Darkness is a reader-supported publication. To support my work, please consider becoming a paid subscriber. A bunch of sadistic murderers at the FDA are not hiding their true intentions. During the scripted performance called VRBAC meeting, they openly discussed a Mengele-style human experiment: A 17-month-old baby was injected with the second\u2026<\/p>\n

___
\nhttps:\/\/lionessofjudah.substack.com\/p\/pure-evil-safety-trials-start-for<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Duke Leads CDC Study Target 6 Month to Under 5-Year-Old Children–Pfizer mRNA + Simultaneous Childhood Vaccines\u2014 Safety Response<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-189201","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts\/189201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=189201"}],"version-history":[{"count":0,"href":"https:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts\/189201\/revisions"}],"wp:attachment":[{"href":"https:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=189201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=189201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=189201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}